IV IDOV-SAFE for advanced solid tumors: safety and effect study
Part of Cancer clinical trials.
This trial tests a new drug called IDOV-SAFE given through a vein. It is for people with advanced solid tumors that have not responded to standard treatments. The study aims to see if the drug is safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your tumor can be measured on scans (at least one measurable lesion).
- You have advanced solid tumors that no longer respond to standard therapy.
- You are mostly able to take care of yourself (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within certain limits.
- You agree to use effective birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IDOV-SAFE that is injected directly into a tumor. It is for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the injection is safe and can shrink the tumor.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
This trial tests a new intravenous drug called IDOV-SAFE in people with advanced solid tumors that have stopped responding to standard treatments or have no effective standard option. The goal is to see if it is safe and effective.
This trial tests an investigational drug called IDOV-Immune for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
Hear when a new Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.